What medication is recommended for treating bulimia nervosa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medication for Bulimia Nervosa

Fluoxetine 60 mg daily, administered in the morning, is the recommended medication for treating bulimia nervosa—this is the only FDA-approved medication with strong evidence for reducing binge-eating and purging behaviors. 1, 2, 3

First-Line Pharmacologic Treatment

  • Fluoxetine at 60 mg/day is the only dose statistically superior to placebo for reducing the frequency of binge-eating and vomiting episodes in bulimia nervosa. 1, 2, 3

  • Standard antidepressant doses of fluoxetine (20 mg) are inadequate and should not be used for bulimia nervosa—the 60 mg dose is essential for therapeutic effect. 2

  • The medication should be administered in the morning as a single daily dose. 1, 3

  • For some patients, titrating up to the 60 mg target dose over several days may be advisable to improve tolerability. 3

When to Initiate Medication

  • The American Psychiatric Association suggests initiating fluoxetine alongside cognitive-behavioral therapy (CBT) as part of comprehensive treatment. 2

  • Alternatively, fluoxetine should be added if there is minimal or no response to psychotherapy alone by 6 weeks of treatment. 2

  • Fluoxetine is particularly useful for patients who have not responded adequately to psychological treatment alone or who have relapsed following psychotherapy. 4

Treatment Duration and Maintenance

  • Systematic evaluation has demonstrated benefit of continuing fluoxetine 60 mg/day for up to 52 weeks in patients who responded during an 8-week acute treatment phase. 3

  • Patients should be periodically reassessed to determine the need for continued maintenance treatment. 3

Combination Therapy Advantage

  • Cognitive-behavioral therapy plus fluoxetine is superior to medication alone in treating bulimia nervosa. 5

  • The combination of medication and psychological treatment produces greater improvement in binge eating and depression compared to placebo plus psychological treatment. 5

  • A two-stage medication intervention using fluoxetine adds modestly but meaningfully to the benefit of psychological treatment. 5

Alternative SSRIs (When Fluoxetine Cannot Be Used)

While fluoxetine is the only FDA-approved medication, other SSRIs have shown efficacy in controlled trials:

  • Sertraline 100 mg/day demonstrated statistically significant reduction in binge-eating crises and purging episodes compared to placebo over 12 weeks. 6

  • Fluvoxamine 200 mg/day showed statistically significant reduction in binge-eating and purging episodes over 12 weeks. 7

  • However, these alternatives lack FDA approval and should only be considered when fluoxetine is contraindicated or not tolerated. 2

Critical Pitfall to Avoid

Do not use 20 mg fluoxetine for bulimia nervosa—only the 60 mg dose has proven efficacy, and using standard antidepressant dosing will result in treatment failure. 2, 3

Integration with Comprehensive Care

  • Medication should be delivered as part of a coordinated multidisciplinary team incorporating medical, psychiatric, psychological, and nutritional expertise. 1

  • Eating disorder-focused cognitive-behavioral therapy remains the cornerstone psychological treatment and should be combined with pharmacotherapy for optimal outcomes. 1, 2

References

Guideline

Treatment Approach for Bulimia Nervosa

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pharmacologic Therapy for Eating Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Medication and psychotherapy in the treatment of bulimia nervosa.

The American journal of psychiatry, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.